AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer
Ayisha Sharma / endpoints - AstraZeneca is spending $100 million upfront to secure ex-China rights for an early-stage cancer drug developed by Jacobio Pharma. The UK drugmaker will be responsible for advancing and selling the oral pan-KRAS inhibitor, JAB-23E73, in ...
AI Summary: Reports indicate that AstraZeneca has struck a global licensing agreement with Jacobio Pharma for its investigational pan‑KRAS inhibitor. With a deal value of up to $2 billion and an upfront commitment, the move is set to reinforce AstraZeneca’s oncology pipeline with next‑generation targeted therapy.
Related Stories
Novartis pays $100M upfront for macrocyclic peptide platform / 4 months
Anthropic launches Claude Science to court pharma and enter drug discovery / 7 days
Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio / 3 months
Sanofi ousts Paul Hudson as Belén Garijo named incoming CEO / 4 months
Novartis buys Myricx Bio to bolster ADC ambitions / 7 hrs
Anthropic buys Coefficient Bio for $400M, betting on AI drug discovery / 3 months
Biogen announces $5.6B acquisition of Apellis Pharma / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Avian Influenza, Alzheimer's disease, Drug Pricing, Obesity and look for the RSS link.
StackHealth Time Machine